Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  GeNeuro    GNRO   CH0308403085

GENEURO

(GNRO)
  Report  
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Paris
08/16/2019 08/19/2019 08/20/2019 08/21/2019 08/22/2019 Date
3.4(c) 3.4(c) 3.43(c) 3.43(c) 3.4 Last
403 2 289 861 174 Volume
-1.45% 0.00% +0.88% 0.00% -0.87% Change
More quotes
Financials (EUR)
Sales 2019 79,3 M
EBIT 2019 -14,1 M
Net income 2019 -14,1 M
Finance 2019 3,58 M
Yield 2019 -
Sales 2020 10,6 M
EBIT 2020 -13,9 M
Net income 2020 -14,2 M
Debt 2020 11,4 M
Yield 2020 -
P/E ratio 2019 -3,57x
P/E ratio 2020 -3,50x
EV / Sales2019 0,59x
EV / Sales2020 5,79x
Capitalization 50,0 M
More Financials
Company
GeNeuro specializes in the development of safe and effective treatments against neurological disorders and autoimmune diseases such as multiple sclerosis or type 1 diabetes by neutralizing causal factors encoded by HERVs, which represent 8% of human DNA. A new frontier pioneered by GeNeuro since... 
More about the company
Latest news on GENEURO
07/19GENEURO : financial information and business update for the second quarter 2019
AQ
07/15GENEURO : Frontiers in Genetics review supports role of hidden DNA viruses in ne..
AQ
06/27GENEURO : PNAS publication supports temelimab's rationale against neurodegenerat..
AQ
06/26GENEURO : PNAS publication supports temelimab's rationale against neurodegenerat..
PU
2018GENEURO : to Present 12 Month Data on Anti-neurodegeneration Effects of GNbAC1 f..
AQ
2018GENEURO : Half-year results
CO
2018GENEURO SA : half-yearly earnings release
2018GENEURO : Half-year report
CO
2018GENEURO : Press Release
CO
2018GENEURO : Proxy Statments
CO
More news
Analyst Recommendations on GENEURO
More recommendations
Sector news : Biotechnology & Medical Research - NEC
06:28aGSK's long acting HIV injection gets boost from study
RE
08/15European Medicines Agency Reviews Arthritis Treatment by Gilead, Galapagos
DJ
08/12REGENERON PHARMACEUTICALS : Two Experimental Ebola Drugs Reduce Mortality Rate
DJ
08/08Sarepta says adverse event report for DMD gene therapy erroneously submitted
RE
08/08AGENUS : FDA Accepts AGEN2373 IND, Triggering $7.5 Million Milestone
DJ
More sector news : Biotechnology & Medical Research - NEC
Chart GENEURO
Duration : Period :
GeNeuro Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GENEURO
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 8,85  €
Last Close Price 3,43  €
Spread / Highest target 209%
Spread / Average Target 158%
Spread / Lowest Target 107%
EPS Revisions
Managers
NameTitle
Jesús Martin-Garcia Chairman & Chief Executive Officer
François Curtin Chief Operating Officer
Miguel Payro Chief Financial Officer
Hervé Perron Chief Scientific Officer
Robert Glanzman Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
GENEURO-0.29%55
IQVIA HOLDINGS INC35.31%30 793
LONZA GROUP36.32%26 936
INCYTE CORPORATION35.35%18 511
CELLTRION, INC.--.--%16 617
EXACT SCIENCES CORPORATION89.32%15 439